StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)

Close on Nov 18, 2026Market cap $528.94MP/E –Yield –

Myriad Genetics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Myriad Genetics's price to book ratio was 1.8× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.5× to 3.5×, with a median of 1.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.8×+0.3
2025Dec 31, 20251.5×−0.2
2024Dec 31, 20241.7×−0.6
2023Dec 29, 20232.3×+1.0
2022Dec 30, 20221.3×−1.0
2021Dec 31, 20212.2×+0.6
2020Dec 31, 20201.6×−0.3
2019Dec 31, 20191.9×−0.1
2018Dec 31, 20182.0×−0.8
2017Dec 29, 20172.7×+1.2
2016Dec 30, 20161.6×−2.8
2015Dec 31, 20154.4×+0.9
2014Dec 31, 20143.5×+1.2
2013Dec 31, 20132.3×−1.2
2012Dec 31, 20123.5×+0.4
2011Dec 30, 20113.1×−0.6
2010Dec 31, 20103.7×−2.2
2009Dec 31, 20095.9×–

More Myriad Genetics figures

See a number that looks wrong?